K
Klaus Charisse
Researcher at Alnylam Pharmaceuticals
Publications - 103
Citations - 9253
Klaus Charisse is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Small interfering RNA & Gene silencing. The author has an hindex of 31, co-authored 96 publications receiving 7942 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Jürgen Soutschek,Akin Akinc,Birgit Bramlage,Klaus Charisse,Rainer Constien,Mary Donoghue,Sayda Elbashir,Anke Geick,Philipp Hadwiger,Jens Harborth,Matthias John,Venkitasamy Kesavan,Gary Lavine,Rajendra K. Pandey,Timothy Racie,Kallanthottathil G. Rajeev,Ingo Röhl,Ivanka Toudjarska,Gang Wang,Silvio Wuschko,David Bumcrot,Victor Koteliansky,Stefan Limmer,Muthiah Manoharan,Hans-Peter Vornlocher +24 more
TL;DR: In this article, chemically modified short interfering RNAs (siRNAs) were used to silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice.
Journal ArticleDOI
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Hyukjin Lee,Abigail K. R. Lytton-Jean,Yi Chen,Kevin T. Love,Angela I. Park,Emmanouil D. Karagiannis,Alfica Sehgal,William Querbes,Christopher Zurenko,Muthusamy Jayaraman,Chang G. Peng,Klaus Charisse,Anna Borodovsky,Muthiah Manoharan,Jessica S. Donahoe,Jessica Truelove,Matthias Nahrendorf,Robert Langer,Daniel G. Anderson +18 more
TL;DR: In this paper, a tetrahedral DNA strand self-assembles into tetrahedron nanoparticles that can deliver small interfering RNA molecules to cells and suppress genes in tumours.
Journal ArticleDOI
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair,Jennifer L. S. Willoughby,Amy Chan,Klaus Charisse,Md. Rowshon Alam,Qianfan Wang,Menno Hoekstra,Pachamuthu Kandasamy,Alexander V Kel'in,Stuart Milstein,Nate Taneja,Jonathan O'Shea,Sarfraz Shaikh,Ligang Zhang,Ronald J. van der Sluis,Michael E. Jung,Akin Akinc,Renta Hutabarat,Satya Kuchimanchi,Kevin Fitzgerald,Tracy Zimmermann,Theo J.C. Van Berkel,Martin Maier,Kallanthottathil G. Rajeev,Muthiah Manoharan +24 more
TL;DR: The optimally chemically modified siRNA-GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a wide range of diseases involving liver-expressed genes.
Journal ArticleDOI
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky,Aldo Grefhorst,Norma N. Anderson,Timothy Racie,Birgit Bramlage,Akin Akinc,David Butler,Klaus Charisse,Robert Dorkin,Yupeng Fan,Christina Gamba-Vitalo,Philipp Hadwiger,Muthusamy Jayaraman,Matthias John,K. Narayanannair Jayaprakash,Martin Maier,Lubomir Nechev,Kallanthottathil G. Rajeev,Timothy Read,Ingo Röhl,Jürgen Soutschek,Pamela Tan,Jamie Wong,Gang Wang,Tracy Zimmermann,Antonin de Fougerolles,Hans-Peter Vornlocher,Robert Langer,Daniel G. Anderson,Muthiah Manoharan,Victor Koteliansky,Jay D. Horton,Kevin Fitzgerald +32 more
TL;DR: PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc is validated, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.
Journal ArticleDOI
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
James E. Dahlman,Carmen M. Barnés,Omar F. Khan,Aude Thiriot,Siddharth Jhunjunwala,Taylor E. Shaw,Yiping Xing,Hendrik B. Sager,Gaurav Sahay,Lauren Speciner,Andrew Bader,Roman L. Bogorad,Hao Yin,Tim Racie,Yizhou Dong,Shan Jiang,Danielle Seedorf,Apeksha Dave,Kamaljeet Singh Sandhu,Matthew J. Webber,Tatiana Novobrantseva,Vera M. Ruda,Abigail K. R. Lytton-Jean,Christopher G. Levins,Brian T. Kalish,Dayna K. Mudge,Mario F. Perez,Ludmila Abezgauz,Partha Dutta,Lynelle P. Smith,Klaus Charisse,Mark W. Kieran,Kevin Fitzgerald,Matthias Nahrendorf,Dganit Danino,Rubin M. Tuder,Ulrich H. von Andrian,Akin Akinc,Dipak Panigrahy,Avi Schroeder,Victor Koteliansky,Robert Langer,Daniel G. Anderson +42 more
TL;DR: These nanoparticles mediate the most durable non-liver silencing reported so far and facilitate the delivery of siRNAs that modify endothelial function in mouse models of vascular permeability, emphysema, primary tumour growth and metastasis.